Haemonetics Net Income vs End Period Cash Flow Analysis

HAE Stock

USD 79.98 0.17 0.21%

Haemonetics financial indicator trend analysis is much more than just examining Haemonetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Haemonetics is a good investment. Please check the relationship between Haemonetics Net Income and its End Period Cash Flow accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Net Income vs End Period Cash Flow

Net Income vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Haemonetics Net Income account and End Period Cash Flow. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Haemonetics' Net Income and End Period Cash Flow is 0.81. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Haemonetics, assuming nothing else is changed. The correlation between historical values of Haemonetics' Net Income and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Haemonetics are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Net Income i.e., Haemonetics' Net Income and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.81

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Haemonetics financial statement analysis. It represents the amount of money remaining after all of Haemonetics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

End Period Cash Flow

Most indicators from Haemonetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Haemonetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.At present, Haemonetics' Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 2.1 B, whereas Enterprise Value Over EBITDA is forecasted to decline to 12.27.

	2023	2024	2025	2026 (projected)
Gross Profit	711.9M	778.5M	895.3M	940.1M
Total Revenue	1.3B	1.4B	1.6B	1.6B

Gross Profit Total Revenue

Haemonetics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock Total Equity	Short Term Investments
Common Stock Shares Outstanding		-0.83	-0.82	-0.74	-0.81	-0.25	-0.09	-0.79	-0.29	-0.69	-0.79	-0.81	0.04	-0.79	-0.31	-0.77	-0.81	-0.09	-0.57	-0.82	-0.66	-0.85	-0.73	-0.8	-0.17	0.3
Total Assets	-0.83		0.96	0.95	0.88	0.56	0.38	0.93	0.38	0.91	0.88	0.99	0.04	0.88	0.63	0.96	0.96	0.23	0.79	0.98	0.86	0.98	0.71	0.97	0.49	-0.41
Short Long Term Debt Total	-0.82	0.96		0.91	0.9	0.36	0.21	0.99	0.21	0.82	0.82	0.96	-0.05	0.82	0.49	0.97	0.96	0.1	0.69	1.0	0.85	0.93	0.77	0.96	0.43	-0.2
Other Current Liab	-0.74	0.95	0.91		0.84	0.51	0.38	0.89	0.22	0.93	0.82	0.94	-0.15	0.82	0.61	0.92	0.93	0.05	0.83	0.94	0.9	0.92	0.64	0.9	0.43	-0.31
Total Current Liabilities	-0.81	0.88	0.9	0.84		0.31	0.22	0.86	0.18	0.8	0.84	0.86	-0.16	0.84	0.47	0.79	0.87	0.04	0.65	0.9	0.78	0.89	0.95	0.83	0.38	-0.25
Total Stockholder Equity	-0.25	0.56	0.36	0.51	0.31		0.79	0.3	0.71	0.64	0.52	0.55	0.32	0.52	0.87	0.43	0.46	0.57	0.64	0.41	0.44	0.57	0.12	0.51	0.62	-0.8
Property Plant And Equipment Net	-0.09	0.38	0.21	0.38	0.22	0.79		0.2	0.4	0.57	0.21	0.39	0.04	0.21	0.81	0.25	0.3	0.41	0.63	0.25	0.35	0.34	0.05	0.27	0.82	-0.7
Net Debt	-0.79	0.93	0.99	0.89	0.86	0.3	0.2		0.15	0.77	0.74	0.95	-0.08	0.74	0.45	0.97	0.94	0.07	0.66	0.98	0.82	0.88	0.74	0.94	0.45	-0.12
Retained Earnings	-0.29	0.38	0.21	0.22	0.18	0.71	0.4	0.15		0.33	0.41	0.38	0.66	0.41	0.49	0.24	0.18	0.69	0.09	0.23	0.22	0.37	0.12	0.41	0.16	-0.52
Accounts Payable	-0.69	0.91	0.82	0.93	0.8	0.64	0.57	0.77	0.33		0.82	0.89	0.01	0.82	0.75	0.82	0.87	0.28	0.88	0.86	0.82	0.92	0.6	0.82	0.58	-0.54
Cash	-0.79	0.88	0.82	0.82	0.84	0.52	0.21	0.74	0.41	0.82		0.83	0.07	1.0	0.55	0.78	0.81	0.17	0.66	0.84	0.78	0.94	0.73	0.81	0.25	-0.46
Non Current Assets Total	-0.81	0.99	0.96	0.94	0.86	0.55	0.39	0.95	0.38	0.89	0.83		0.03	0.83	0.6	0.97	0.95	0.23	0.77	0.98	0.86	0.95	0.69	0.98	0.51	-0.37
Non Currrent Assets Other	0.04	0.04	-0.05	-0.15	-0.16	0.32	0.04	-0.08	0.66	0.01	0.07	0.03		0.07	0.13	0.0	-0.08	0.65	-0.23	-0.05	-0.19	0.04	-0.17	0.11	0.07	-0.23
Cash And Short Term Investments	-0.79	0.88	0.82	0.82	0.84	0.52	0.21	0.74	0.41	0.82	1.0	0.83	0.07		0.55	0.78	0.81	0.17	0.66	0.84	0.78	0.94	0.73	0.81	0.25	-0.46
Net Receivables	-0.31	0.63	0.49	0.61	0.47	0.87	0.81	0.45	0.49	0.75	0.55	0.6	0.13	0.55		0.52	0.57	0.45	0.69	0.53	0.56	0.65	0.29	0.52	0.69	-0.66
Non Current Liabilities Total	-0.77	0.96	0.97	0.92	0.79	0.43	0.25	0.97	0.24	0.82	0.78	0.97	0.0	0.78	0.52		0.95	0.13	0.71	0.98	0.85	0.91	0.61	0.96	0.44	-0.22
Inventory	-0.81	0.96	0.96	0.93	0.87	0.46	0.3	0.94	0.18	0.87	0.81	0.95	-0.08	0.81	0.57	0.95		0.08	0.82	0.97	0.81	0.95	0.71	0.93	0.49	-0.36
Other Current Assets	-0.09	0.23	0.1	0.05	0.04	0.57	0.41	0.07	0.69	0.28	0.17	0.23	0.65	0.17	0.45	0.13	0.08		0.11	0.11	-0.01	0.22	-0.03	0.28	0.41	-0.48
Other Stockholder Equity	-0.57	0.79	0.69	0.83	0.65	0.64	0.63	0.66	0.09	0.88	0.66	0.77	-0.23	0.66	0.69	0.71	0.82	0.11		0.73	0.7	0.8	0.43	0.68	0.66	-0.64
Total Liab	-0.82	0.98	1.0	0.94	0.9	0.41	0.25	0.98	0.23	0.86	0.84	0.98	-0.05	0.84	0.53	0.98	0.97	0.11	0.73		0.87	0.95	0.76	0.96	0.44	-0.24
Property Plant And Equipment Gross	-0.66	0.86	0.85	0.9	0.78	0.44	0.35	0.82	0.22	0.82	0.78	0.86	-0.19	0.78	0.56	0.85	0.81	-0.01	0.7	0.87		0.83	0.64	0.8	0.36	-0.2
Total Current Assets	-0.85	0.98	0.93	0.92	0.89	0.57	0.34	0.88	0.37	0.92	0.94	0.95	0.04	0.94	0.65	0.91	0.95	0.22	0.8	0.95	0.83		0.73	0.92	0.43	-0.48
Short Term Debt	-0.73	0.71	0.77	0.64	0.95	0.12	0.05	0.74	0.12	0.6	0.73	0.69	-0.17	0.73	0.29	0.61	0.71	-0.03	0.43	0.76	0.64	0.73		0.68	0.25	-0.1
Intangible Assets	-0.8	0.97	0.96	0.9	0.83	0.51	0.27	0.94	0.41	0.82	0.81	0.98	0.11	0.81	0.52	0.96	0.93	0.28	0.68	0.96	0.8	0.92	0.68		0.44	-0.31
Common Stock Total Equity	-0.17	0.49	0.43	0.43	0.38	0.62	0.82	0.45	0.16	0.58	0.25	0.51	0.07	0.25	0.69	0.44	0.49	0.41	0.66	0.44	0.36	0.43	0.25	0.44		-0.51
Short Term Investments	0.3	-0.41	-0.2	-0.31	-0.25	-0.8	-0.7	-0.12	-0.52	-0.54	-0.46	-0.37	-0.23	-0.46	-0.66	-0.22	-0.36	-0.48	-0.64	-0.24	-0.2	-0.48	-0.1	-0.31	-0.51

Click cells to compare fundamentals

Haemonetics Account Relationship Matchups

Haemonetics fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Common Stock Shares Outstanding	51.4M	51.4M	51.4M	50.7M	45.7M	42.5M
Total Assets	1.9B	1.9B	2.2B	2.5B	2.8B	3.0B
Short Long Term Debt Total	780.8M	765.9M	807.8M	1.2B	1.4B	1.5B
Other Current Liab	121.8M	145.9M	185.6M	164.2M	188.8M	198.3M
Total Current Liabilities	442.3M	251.8M	300.4M	578.1M	664.8M	698.1M
Total Stockholder Equity	749.4M	818.0M	960.0M	820.8M	944.0M	546.7M
Property Plant And Equipment Net	258.5M	310.9M	366.6M	284.1M	326.7M	189.6M
Net Debt	521.3M	481.4M	629.0M	918.0M	1.1B	1.1B
Retained Earnings	202.4M	253.2M	360.5M	352.2M	405.0M	285.0M
Accounts Payable	58.4M	63.9M	73.4M	67.0M	77.0M	80.9M
Cash	259.5M	284.5M	178.8M	306.8M	352.8M	370.4M
Non Current Assets Total	1.1B	1.2B	1.4B	1.5B	1.7B	1.8B
Non Currrent Assets Other	63.2M	107.0M	81.1M	164.1M	188.7M	101.3M
Cash And Short Term Investments	259.5M	284.5M	178.8M	306.8M	352.8M	370.4M
Net Receivables	159.4M	179.1M	206.6M	202.7M	233.1M	123.7M
Liabilities And Stockholders Equity	1.9B	1.9B	2.2B	2.5B	2.8B	3.0B
Non Current Liabilities Total	668.0M	865.0M	935.2M	1.1B	1.2B	1.3B
Inventory	293.0M	259.4M	317.2M	365.1M	419.9M	440.9M
Other Current Assets	44.1M	46.7M	66.3M	60.4M	69.5M	52.6M
Other Stockholder Equity	572.5M	594.7M	634.6M	523.3M	601.8M	631.8M
Total Liab	1.1B	1.1B	1.2B	1.6B	1.9B	2.0B
Property Plant And Equipment Gross	869.1M	944.2M	959.2M	837.2M	962.8M	1.0B
Total Current Assets	756.0M	769.7M	768.9M	935.0M	1.1B	1.1B
Accumulated Other Comprehensive Income	(26.0M)	(30.4M)	(35.6M)	(55.1M)	(63.3M)	(60.2M)
Short Term Debt	221.3M	11.8M	10.2M	303.6M	349.1M	366.5M
Intangible Assets	310.3M	275.8M	406.1M	455.7M	524.1M	550.3M
Common Stock	511K	504K	508K	482K	554.3K	423.5K
Other Assets	67.7M	58.8M	1.0	1K	1.2K	1.1K
Long Term Debt	559.4M	754.1M	797.6M	921.2M	1.1B	1.1B
Good Will	467.3M	466.2M	565.1M	604.3M	694.9M	729.7M
Property Plant Equipment	258.5M	310.9M	366.6M	331.5M	381.3M	226.7M
Current Deferred Revenue	26.8M	30.2M	31.2M	43.3M	49.9M	52.3M
Net Tangible Assets	243.4M	(100.3M)	(28.1M)	76.0M	68.4M	65.0M
Retained Earnings Total Equity	78.5M	158.0M	202.4M	253.2M	227.9M	230.9M
Long Term Debt Total	559.4M	754.1M	797.6M	921.2M	1.1B	1.1B
Capital Surpluse	572.5M	594.7M	634.6M	523.3M	601.8M	532.6M
Deferred Long Term Liab	10.6M	43.8M	28.7M	36.2M	41.6M	26.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

JBL	Jabil Circuit
MRK	Merck Company
AMGN	Amgen Inc

When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:

How To Invest In Haemonetics

Details

Is Haemonetics Stock a good investment?

Details

What is Haemonetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.227

Earnings Share

3.42

Revenue Per Share

27.213

Quarterly Revenue Growth

(0.05)

Return On Assets

0.0636

The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Haemonetics Net Income vs End Period Cash Flow Analysis

Net Income vs End Period Cash Flow

Net Income vs End Period Cash Flow Correlation Analysis

Correlation Coefficient

Net Income

End Period Cash Flow

Haemonetics fundamental ratios Correlations

Haemonetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Haemonetics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Assets

Total Current Assets	- 0.85	Common Stock Shares Outstanding
Total Assets	- 0.83	Common Stock Shares Outstanding
Total Liab	- 0.82	Common Stock Shares Outstanding
Short Long Term Debt Total	- 0.82	Common Stock Shares Outstanding
Inventory	- 0.81	Common Stock Shares Outstanding
Non Current Assets Total	- 0.81	Common Stock Shares Outstanding